AVADEL PHARMACEUTICALS PLC Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Avadel Pharmaceuticals Plc quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Avadel Pharmaceuticals Plc Debt-to-equity for the quarter ending September 30, 2024 was 108 %, a 56.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 108 -141 -56.5% Sep 30, 2024
Q2 2024 100 -668 -87% Jun 30, 2024
Q1 2024 75.6 +944 Mar 31, 2024
Q4 2023 134 -3.36K -96.2% Dec 31, 2023
Q3 2023 249 -307 -55.2% Sep 30, 2023
Q2 2023 768 +480 +166% Jun 30, 2023
Q1 2023 -869 -1.06K -560% Mar 31, 2023
Q4 2022 3.49K +3.34K +2208% Dec 31, 2022
Q3 2022 556 +433 +353% Sep 30, 2022
Q2 2022 289 +182 +172% Jun 30, 2022
Q1 2022 189 +93.6 +98.2% Mar 31, 2022
Q4 2021 151 +34.3 +29.3% Dec 31, 2021
Q3 2021 123 -65.8 -34.9% Sep 30, 2021
Q2 2021 106 -336 -75.9% Jun 30, 2021
Q1 2021 95.3 +1.82K Mar 31, 2021
Q4 2020 117 +991 Dec 31, 2020
Q3 2020 189 +1.62K Sep 30, 2020
Q2 2020 442 -1.4K -76% Jun 30, 2020
Q1 2020 -1.73K -2.3K -400% Mar 31, 2020
Q4 2019 -874 -1.25K -334% Dec 31, 2019
Q3 2019 -1.43K -1.7K -631% Sep 30, 2019
Q2 2019 1.84K +1.6K +670% Jun 30, 2019
Q1 2019 575 +345 +150% Mar 31, 2019
Q4 2018 373 +143 +62.4% Dec 31, 2018
Q3 2018 269 -10 -3.59% Sep 30, 2018
Q2 2018 239 -132 -35.6% Jun 30, 2018
Q1 2018 230 -197 -46.1% Mar 31, 2018
Q4 2017 230 -168 -42.2% Dec 31, 2017
Q3 2017 279 -46 -14.1% Sep 30, 2017
Q2 2017 371 Jun 30, 2017
Q1 2017 428 Mar 31, 2017
Q4 2016 398 Dec 31, 2016
Q3 2016 325 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.